Get the Stockscreener App
54.91
4.71%
2.47
After Hours:
55.59
0.68
+1.24%
Tempus Ai Inc stock is traded at $54.91, with a volume of 6.46M.
It is up +4.71% in the last 24 hours and down -21.04% over the past month.
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
See More
Previous Close:
$52.44
Open:
$53.46
24h Volume:
6.46M
Relative Volume:
1.25
Market Cap:
$9.77B
Revenue:
$803.32M
Net Income/Loss:
$-709.10M
P/E Ratio:
-7.0395
EPS:
-7.8003
Net Cash Flow:
$-212.68M
1W Performance:
-8.21%
1M Performance:
-21.04%
6M Performance:
-1.12%
1Y Performance:
-15.51%
1-Day Range:
$52.96
$55.55
1-Week Range:
$49.88
$59.99
52-Week Range:
$36.22
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Name
Tempus Ai Inc
Sector
Industry
Phone
800-976-5448
Address
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, HQY, DOCS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
54.91 | 9.33B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
VEEV
Veeva Systems Inc
|
183.65 | 30.22B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
BTSG
Brightspring Health Services Inc
|
39.68 | 6.92B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
79.45 | 6.77B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
27.73 | 6.27B | 550.17M | 201.35M | 232.07M | 1.00 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-21-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-20-25 | Initiated | Canaccord Genuity | Buy |
| Sep-02-25 | Initiated | H.C. Wainwright | Buy |
| Apr-21-25 | Initiated | BTIG Research | Buy |
| Feb-25-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-05-25 | Resumed | TD Cowen | Buy |
| Dec-13-24 | Initiated | Wolfe Research | Outperform |
| Dec-09-24 | Initiated | Guggenheim | Buy |
| Nov-11-24 | Downgrade | Stifel | Buy → Hold |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-12-24 | Initiated | Piper Sandler | Neutral |
| Jul-09-24 | Initiated | BofA Securities | Buy |
| Jul-09-24 | Initiated | JP Morgan | Overweight |
| Jul-09-24 | Initiated | Longbow | Buy |
| Jul-09-24 | Initiated | Loop Capital | Buy |
| Jul-09-24 | Initiated | Morgan Stanley | Overweight |
| Jul-09-24 | Initiated | Needham | Buy |
| Jul-09-24 | Initiated | Stifel | Buy |
| Jul-09-24 | Initiated | TD Cowen | Buy |
| Jul-09-24 | Initiated | William Blair | Outperform |
View All
Tempus Ai Inc Stock (TEM) Latest News
Artificial Intelligence Stocks To Follow NowFebruary 6th - MarketBeat
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Position in Tempus AI, Inc. $TEM - MarketBeat
Do Tempus AI’s New IPS Results Reframe TEM’s Edge In Precision Oncology Diagnostics? - Yahoo Finance
Best Artificial Intelligence Stocks To ResearchFebruary 5th - MarketBeat
Can Tempus AI’s (TEM) Immune Profile Score Redefine Its Edge In Precision Oncology Data? - simplywall.st
Tempus AI Links Hereditary Cancer Data And Immune Scoring To Growth Prospects - Yahoo Finance
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Globe and Mail
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Tempus AI, Inc. (TEM): A Bull Case Theory - Finviz
Insider Sell: David Epstein Sells 370 Shares of Tempus AI Inc (T - GuruFocus
Tempus AI (NASDAQ:TEM) Director Sells $21,981.70 in Stock - MarketBeat
Promising Artificial Intelligence Stocks To Watch NowFebruary 4th - MarketBeat
RSI Alert: Tempus AI (TEM) Now Oversold - Nasdaq
Tempus AI Stock (TEM) Opinions on Q4 Earnings Beat - Quiver Quantitative
New DNA study could sharpen cancer risk for thousands of patients - stocktitan.net
Tempus AI, Inc. (NASDAQ:TEM) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
AI in Oncology Market to Reach US$ 22.85 Billion by 2033, Growing - openPR.com
Best Artificial Intelligence Stocks To Watch TodayFebruary 2nd - MarketBeat
Tempus AI, Inc. (TEM) Investor Outlook: Navigating a 46.97% Upside Amidst High Growth and Strategic Collaborations - DirectorsTalk Interviews
What's Going On With Tempus AI Stock Monday?Tempus AI (NASDAQ:TEM) - Benzinga
RNA in cancer gene tests found 1 in 25 positives otherwise missed - stocktitan.net
Artificial Intelligence Stocks To Keep An Eye OnFebruary 1st - MarketBeat
Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones - Finviz
Mirae Asset Global Investments Co. Ltd. Increases Stake in Tempus AI, Inc. $TEM - MarketBeat
Artificial Intelligence Stocks To Follow TodayJanuary 31st - MarketBeat
Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 166,250 Shares of Stock - MarketBeat
Promising Artificial Intelligence Stocks To Watch TodayJanuary 30th - MarketBeat
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals - MSN
Tempus AI Inc (TEM) Trading Down 4.09% on Jan 30 - GuruFocus
Esoteric Testing Research Report 2026 - GlobeNewswire Inc.
Is Tempus AI Inc. stock a good dividend stockWeekly Trade Review & Community Verified Swing Trade Signals - mfd.ru
Tempus AI's COO Ryan Fukushima sells shares worth $2.27 million - MSN
Artificial Intelligence Stocks Worth WatchingJanuary 29th - MarketBeat
Top Artificial Intelligence Stocks To Watch TodayJanuary 3rd - MarketBeat
TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom? - Finviz
21,000 Shares in Tempus AI, Inc. $TEM Purchased by Hussman Strategic Advisors Inc. - MarketBeat
Should Tempus AI’s (TEM) New Immunotherapy Prediction Data Shift How Investors View Its Moat? - simplywall.st
Tempus AI (TEM) Valuation Check After New Immune Profile Score Data And High Profile Investor Interest - Yahoo Finance
Tempus AI study shows improved cancer immunotherapy prediction By Investing.com - Investing.com Australia
Tempus AI Expands Cancer Tools As Shares Trade Below Analyst Estimates - Yahoo Finance
Tempus AI’s Clinical Breakthrough: A Potential Catalyst for Growth - AD HOC NEWS
Tempus AI IPS Study Points To Wider Immunotherapy Use And Investor Interest - simplywall.st
Is It Time To Reassess Tempus AI (TEM) After Its Strong 1 Year Share Price Run? - Yahoo Finance UK
Tempus says AI-powered biomarker improves immunotherapy predictions - FirstWord Pharma
Artificial Intelligence Stocks To Watch NowJanuary 27th - MarketBeat
Promising Artificial Intelligence Stocks To Follow TodayJanuary 4th - MarketBeat
Nancy Pelosi Just Doubled Down on AI Again - Yahoo Finance
Tempus Says Study Shows AI-Driven Test More Accurately Predicts Immunotherapy Benefits - marketscreener.com
Tempus Ai, Inc. Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers - marketscreener.com
Tempus AI study shows improved cancer immunotherapy prediction - Investing.com
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers - Business Wire
Tempus Ai Inc Stock (TEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.44%
16.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):